The name highlights the first authorization of an mRNA vaccine, as well as the “joint global efforts that made this achievement possible with unprecedented rigor and efficiency,” Pfizer said in December after the vaccine received conditional marketing authorization from the European Commission.
Among other names in the running were Covuity, RnaxCovi, Kovimerna and RNXtract, according to NPR.
Moderna’s vaccine will be marketed as Spikevax if it receives full FDA approval, according to the European Medicines Agency.
